LEVOSIMENDAN


Product Type: cardiac therapy, cardiac stimulant

CAS Number: 141505-33-1

Common Indications: calcium sensitizer used in the management of acute heart failure.

Product Status: Commercial

Structural formula:



Our API Levosimendan is manufacture in accordance with cGMP and stringent international quality standards. Our quality control follows every stage from development of analytical methods to the control of manufacturing process.

Levosimendan potentiates the calcium sensitivity of contractile proteins by binding to cardiac troponin C by a calcium-dependent mechanism. Levosimendan increases contractile force, but without affecting ventricular relaxation.

CHARACTERISTICS AND THERAPEUTIC USE AS A DRUG

Levosimendan is indicated for the short-term treatment of acute severe decompensation of chronic heart failure in situations where conventional treatment is not sufficient, and in cases where inotropic support is considered appropriate.


FINISHED DOSAGE FORMS

INJECTABLE:


Concentrate for solution for infusion: 2,5mg/ml

MARKET STATUS

API CONSUMPTION (kg)



SALES FDF (USD) 2022-2023



OUR API

KEY POINTS:

- 20 M USD global market sales in 2023.
- Global consumption of 4 MT.
- Well established market in Brazil.
- Few API manufacturers to cover worldwide demand.

CONTRACT MANUFACTURER:

Relevant Information:

- EU-GMP certificate.
- Plant successfully audited by european customers.
- CEP for other products available.
- Competitive price.

DOCUMENTATION:

- DMF available
- CoA available
- MSDS available

• Other information:

- **Stabilty studies** available
- **Samples available**

Supply:

- We have a long lasting strategic commitment to this product that ensures continuity an security of supply.

MORE INFORMATION

FOR MORE INFORMATION PLEASE CONTACT:

NARCIS BRUGADA (humanapis@suanfarma.com)

HUMAN API BUSINESS UNIT DIRECTOR

LEVOSIMENDAN

PATENT PROTECTION

OFF